Rezdiffra (Resmetirom) Anesthesia and Perioperative Interactions: What Patients and Clinicians Need to Know

What Is Resmetirom and Why Does Perioperative Management Matter?

Resmetirom is a once-daily oral THR-β agonist approved by the FDA in March 2024 under the brand name Rezdiffra for adults with noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) and moderate-to-advanced liver fibrosis (stage F2 or F3). [1] The MAESTRO-NASH trial (N=966) demonstrated that 80 mg and 100 mg daily doses produced NASH resolution in 25.9% and 29.9% of patients respectively at 52 weeks, versus 9.7% on placebo (P<0.001). [2]

Patients taking Rezdiffra who need surgery carry a layered risk profile. They already have significant liver disease with altered drug metabolism, they are often obese with associated cardiopulmonary comorbidities, and they are now on a drug that inhibits multiple metabolic pathways relevant to anesthesia. Failing to account for these factors before the induction of general anesthesia can result in prolonged drug effects, hemodynamic instability, or excess bleeding.

Who Is Most Likely to Need Surgery While on Resmetirom?

The MASH patient population skews toward middle-aged adults with metabolic syndrome, type 2 diabetes, and obesity. These individuals have elevated rates of cholecystectomy (gallstone disease is common in rapid-weight-change populations), bariatric surgery, orthopedic procedures, and cardiovascular interventions. The overlap between patients on resmetirom and patients scheduled for surgery is not trivial.

The Regulatory Baseline: What the FDA Label Says

The approved Rezdiffra prescribing information explicitly flags resmetirom as a CYP3A4 inhibitor and an inhibitor of hepatic uptake transporters OATP1B1 and OATP1B3, as well as the efflux transporter P-glycoprotein (P-gp). [1] The label advises monitoring or dose adjustment for co-administered drugs that are sensitive substrates of these pathways. Anesthesiology does not have a specific section in the label, but the transporter and enzyme interactions described there apply directly to common perioperative medications.

CYP3A4 Inhibition and Its Impact on Anesthetic Drugs

Resmetirom inhibits CYP3A4 in a clinically relevant way. CYP3A4 is the single most important drug-metabolizing enzyme in the human body, responsible for the primary clearance of an estimated 30 to 50 percent of all prescription drugs. [3]

Opioids

Fentanyl, alfentanil, sufentanil, and oxycodone are all CYP3A4 substrates. Co-administration with a CYP3A4 inhibitor can raise plasma concentrations meaningfully, increasing the risk of respiratory depression and prolonged sedation. The FDA-approved labeling for fentanyl specifically warns that CYP3A4 inhibitors may increase fentanyl plasma concentrations and produce potentially fatal respiratory depression. [4] Anesthesiologists managing patients on resmetirom should anticipate reduced opioid dosage requirements and extend post-operative monitoring periods.

Morphine is not a CYP3A4 substrate and may be a preferable alternative in patients where the interaction is a strong concern, though its active metabolite morphine-6-glucuronide accumulates in hepatic impairment, which is already present in this population.

Benzodiazepines

Midazolam is a well-established sensitive CYP3A4 substrate used as a benchmark in drug interaction studies. [5] When CYP3A4 is inhibited, midazolam AUC can increase by more than two-fold depending on the inhibitor potency. Resmetirom's inhibitory constant (Ki) for CYP3A4 has not been published in as granular a form as classic strong inhibitors like itraconazole, but the FDA label classifies the interaction as clinically significant enough to warrant monitoring. [1] Lorazepam, which is glucuronidated rather than CYP3A4-metabolized, is a safer benzodiazepine option for pre-medication in the resmetirom patient.

Neuromuscular Blocking Agents

Rocuronium is partially eliminated via P-gp and OATP1B1/1B3-mediated hepatic uptake. Because resmetirom inhibits both transporters, rocuronium clearance may be reduced. The clinical magnitude is not yet defined in prospective trials for resmetirom specifically, but analogous data from other OATP1B inhibitors (such as rifampin in induction versus cyclosporin) support the theoretical concern. [6] Quantitative neuromuscular monitoring with a train-of-four (TOF) ratio should be used to guide reversal rather than relying on fixed time-based protocols.

Vecuronium shares a similar hepatic elimination pathway and warrants the same caution. Cisatracurium, cleared by Hofmann degradation independent of hepatic enzymes, is a rational alternative when prolonged neuromuscular blockade is a concern.

Thyroid Hormone Receptor Agonism and Cardiac Hemodynamics Under Anesthesia

This is the most under-discussed perioperative concern with resmetirom. The drug selectively activates THR-β, which is the dominant thyroid receptor isoform in the liver. THR-α, expressed primarily in the heart, is largely spared. This selectivity is intentional. However, "largely spared" is not the same as "completely spared."

Heart Rate Effects

In the MAESTRO-NASH trial, resmetirom produced small but measurable increases in resting heart rate of approximately 1 to 2 beats per minute compared with placebo. [2] Under volatile halogenated anesthetics such as sevoflurane or desflurane, baseline sympathetic tone is reduced and the heart is sensitized to catecholamines. Any background THR-β-mediated chronotropy is more physiologically significant when the patient has limited autonomic reserve. In patients with pre-existing atrial fibrillation or supraventricular tachycardia, the anesthesiologist should be briefed about resmetirom use before induction.

Oxygen Consumption and Temperature Regulation

Thyromimetic agents increase basal metabolic rate by upregulating mitochondrial uncoupling and thermogenesis. The liver, the primary target tissue for resmetirom, consumes a disproportionately large share of the body's oxygen at rest. Under general anesthesia with reduced perfusion to visceral beds, the interaction between elevated hepatic oxygen demand and reduced oxygen delivery could theoretically worsen ischemia-reperfusion injury during hepatic procedures or prolonged laparotomies. This concern is speculative in the absence of prospective data for resmetirom, but it is consistent with known THR physiology. [7]

Anticoagulation, Hemostasis, and Resmetirom

Patients with MASH and F2-F3 fibrosis already have measurably compromised synthetic function compared with healthy livers, though not to the degree seen in cirrhosis. Resmetirom's trial population excluded cirrhosis, but F3 fibrosis represents a meaningful step toward compromised clotting factor production.

Warfarin and Vitamin K Antagonists

The Rezdiffra label identifies a potential interaction with warfarin. Resmetirom inhibits OATP1B1/1B3, which are involved in hepatic uptake of warfarin's metabolites and in the enterohepatic cycling of bile acids that affect fat-soluble vitamin absorption. [1] Any change in vitamin K absorption or hepatic synthetic function could alter INR. Patients on warfarin should have INR checked within one week of starting or stopping resmetirom. The perioperative team must verify INR is within target range before neuraxial anesthesia or procedures with major bleeding risk.

Direct Oral Anticoagulants (DOACs)

Apixaban and rivaroxaban are both P-gp and CYP3A4 substrates. Resmetirom's dual inhibition of CYP3A4 and P-gp could raise DOAC plasma concentrations, potentially increasing bleeding risk. [8] Dabigatran is a P-gp substrate (not CYP3A4) and faces a similar concern. If a patient takes a DOAC and resmetirom, the surgical team should factor the additive pharmacokinetic effect into the hold period calculation. Standard DOAC hold guidelines (24 hours for apixaban/rivaroxaban in low-bleeding procedures, 48 hours for high-risk) may need to be extended.

Statins and Perioperative Considerations

Many MASH patients take statins. Rosuvastatin and atorvastatin are OATP1B1/1B3 substrates, and resmetirom inhibition of these transporters raises statin plasma levels. [1] This is relevant to anesthesia because statin-induced myopathy can complicate postoperative ambulation and be mistaken for surgical pain. Statin levels should be reviewed, and CK checked if myopathy symptoms are present.

Alcohol, Liver Function, and Resmetirom: The Perioperative Context

Can You Drink on Rezdiffra?

Alcohol consumption is directly contraindicated in MASH management. The AASLD practice guidance on NAFLD/MASH states explicitly that alcohol abstinence is the single highest-yield lifestyle intervention for patients with steatohepatitis, irrespective of pharmacotherapy. [9] Resmetirom's prescribing information does not list alcohol as a pharmacokinetic drug-drug interaction, and there is no published data showing resmetirom alters ethanol metabolism via ADH or CYP2E1. However, alcohol worsens hepatic fibrosis through multiple oxidative stress pathways, and the patient population prescribed resmetirom should abstain regardless of the interaction question.

In the perioperative context, acute alcohol intoxication causes CYP2E1 saturation and CYP3A4 suppression. Chronic heavy alcohol use induces CYP2E1 and CYP3A4. Either state alters the metabolic environment that resmetirom operates within, making drug level prediction less reliable. Anesthesia teams should screen for active alcohol use disorder in all MASH surgical patients as part of standard preoperative evaluation.

Hepatic Impairment and Dose Adjustments

The Rezdiffra label specifies that resmetirom has not been studied in patients with severe hepatic impairment (Child-Pugh C). For patients with Child-Pugh A (mild), no dose adjustment is needed. Child-Pugh B (moderate impairment) data are limited. [1] Before surgery, a hepatologist should assess whether the patient's liver synthetic function has changed since resmetirom was initiated, because progressive fibrosis or a superimposed hepatic insult could shift the patient into a higher Child-Pugh class and change the drug's clearance.

Practical Perioperative Protocol: Hold and Restart Guidance

No published randomized trial has defined an optimal hold period for resmetirom before surgery. The following framework is built from the drug's pharmacokinetic profile, its mechanism of enzyme and transporter inhibition, and analogous guidance for other hepatically-metabolized drugs in similar classes.

Pre-operative Hold

Resmetirom has a terminal half-life of approximately 5.5 hours. Five half-lives, representing greater than 97% clearance, occur within approximately 28 hours. However, enzyme inhibition can persist beyond the time drug concentrations fall, because CYP3A4 induction after inhibitor washout takes 24 to 72 hours depending on baseline enzyme activity. [10]

Recommended hold for elective surgery:

• Minor procedures (endoscopy, skin surgery, minor orthopedic): 24 hours before procedure.
• Intermediate procedures (laparoscopic abdominal, joint replacement): 48 hours before procedure.
• Major hepatic, cardiovascular, or transplant surgery: discuss with hepatology and anesthesiology; a 72-hour hold with confirmation of stable liver function tests is reasonable.

All holds are subject to individualized physician judgment. Patients should not stop resmetirom without explicit instruction from their prescribing clinician.

Intraoperative Considerations

• Use quantitative TOF monitoring for all neuromuscular blocking agents.
• Prefer lorazepam over midazolam for pre-medication if benzodiazepine is needed.
• Prefer cisatracurium for neuromuscular blockade in prolonged hepatic procedures.
• Prefer morphine or hydromorphone over fentanyl if opioid is needed and CYP3A4 interaction is a concern, but adjust dose for hepatic impairment.
• Confirm INR <1.5 before neuraxial anesthesia.
• Maintain mean arterial pressure above 65 mmHg to protect hepatic perfusion.

Post-operative Restart

Resmetirom should be restarted only after:

1. The patient can tolerate oral medications without nausea or vomiting.
2. AST, ALT, and bilirubin are at or near the patient's individual baseline.
3. Any active bleeding source has been controlled.
4. Co-administered anticoagulants (if applicable) have been restarted at safe therapeutic levels.

For most minor surgeries, restart within 24 to 48 hours post-operatively is appropriate. For major abdominal or hepatic surgery, restart timing should be decided jointly by the gastroenterologist or hepatologist and the surgical team, often not before day 3 to 5 post-operatively.

Drug-Specific Interaction Summary Table

| Drug Category | Example Agents | Mechanism with Resmetirom | Clinical Action | |---|---|---|---| | Opioid analgesics | Fentanyl, oxycodone | CYP3A4 inhibition raises plasma levels | Reduce dose; extend monitoring | | Benzodiazepines | Midazolam | CYP3A4 inhibition raises AUC | Prefer lorazepam; titrate carefully | | Neuromuscular blockers | Rocuronium, vecuronium | OATP1B1/P-gp inhibition reduces clearance | Use TOF; consider cisatracurium | | DOACs | Apixaban, rivaroxaban | CYP3A4 + P-gp inhibition raises DOAC levels | Extended hold period; check renal function | | Warfarin | Warfarin | OATP/hepatic effect on synthesis/absorption | Check INR within 7 days of change | | Statins | Rosuvastatin, atorvastatin | OATP1B1/1B3 inhibition raises statin levels | Check CK if myopathy symptoms | | Volatile anesthetics | Sevoflurane, desflurane | THR-β-mediated chronotropy under low sympathetic tone | Monitor HR/rhythm; inform anesthesiologist |

Special Populations

Patients With Obesity and Bariatric Surgery

Resmetirom is frequently prescribed to patients who are also candidates for bariatric surgery. Post-bariatric patients have significantly altered drug absorption due to reduced gastric volume, changed intestinal transit, and, in Roux-en-Y gastric bypass, bypassed duodenum and proximal jejunum. These changes affect oral bioavailability of resmetirom. The drug has not been studied specifically in post-bariatric patients, and gastroenterologists should assess whether the labeled dose provides equivalent exposure after bariatric anatomy changes. [1]

Patients With Type 2 Diabetes

Approximately 50 percent of patients in the MAESTRO-NASH trial had type 2 diabetes at baseline. [2] Anesthesia in diabetic patients requires perioperative glucose management. Resmetirom itself does not directly affect insulin secretion or glucose clearance, but the background metabolic syndrome creates the standard perioperative hyperglycemia risk. The ACC/AHA 2014 perioperative guidelines recommend targeting intraoperative glucose below 180 mg/dL in non-cardiac surgery. [11]

When to Consult Hepatology Before Surgery

A hepatology pre-surgical consult is appropriate whenever a resmetirom patient faces:

• Major abdominal, hepatic, or transplant surgery.
• Any surgery requiring general anesthesia when the patient has stage F3 fibrosis confirmed on biopsy.
• Planned neuraxial anesthesia with unclear coagulation status.
• Active titration of warfarin or a DOAC in addition to resmetirom.
• Any recent change in liver enzymes greater than two times the upper limit of normal without a clear explanation.

The hepatologist should document a current Child-Pugh or MELD-Na score, confirm no interval progression to cirrhosis, and advise whether the planned procedure carries excess hepatic decompensation risk.

What Patients Should Tell Their Surgical Team

Patients prescribed Rezdiffra often do not know to disclose it proactively because it is still new to both patients and many non-gastroenterology clinicians. The drug's March 2024 approval means that a large share of practicing anesthesiologists may not yet have encountered it in clinical practice.

Patients should confirm the following at their pre-operative assessment:

• The name of the drug (resmetirom / Rezdiffra), the dose (80 mg or 100 mg), and how long they have been taking it.
• The name of the prescribing physician and their contact information.
• Whether they take any anticoagulants in addition to resmetirom.
• Whether they have had any recent liver function tests and what the results showed.
• Any recent changes in stool color, skin jaundice, easy bruising, or abdominal swelling, which could suggest undetected progression to more advanced liver disease.

Sharing this information at the time of the pre-anesthesia assessment, not on the day of surgery, gives the team time to adjust the anesthetic plan.